A Newly Defined and Xeno-Free Culture Medium Supports Every-Other-Day Medium Replacement in the Generation and Long-Term Cultivation of Human Pluripotent Stem Cells
- PMID: 27606941
- PMCID: PMC5016087
- DOI: 10.1371/journal.pone.0161229
A Newly Defined and Xeno-Free Culture Medium Supports Every-Other-Day Medium Replacement in the Generation and Long-Term Cultivation of Human Pluripotent Stem Cells
Abstract
Human pluripotent stem cells (hPSCs) present an unprecedented opportunity to advance human health by offering an alternative and renewable cell resource for cellular therapeutics and regenerative medicine. The present demand for high quality hPSCs for use in both research and clinical studies underscores the need to develop technologies that will simplify the cultivation process and control variability. Here we describe the development of a robust, defined and xeno-free hPSC medium that supports reliable propagation of hPSCs and generation of human induced pluripotent stem cells (hiPSCs) from multiple somatic cell types; long-term serial subculturing of hPSCs with every-other-day (EOD) medium replacement; and banking fully characterized hPSCs. The hPSCs cultured in this medium for over 40 passages are genetically stable, retain high expression levels of the pluripotency markers TRA-1-60, TRA-1-81, Oct-3/4 and SSEA-4, and readily differentiate into ectoderm, mesoderm and endoderm. Importantly, the medium plays an integral role in establishing a cGMP-compliant process for the manufacturing of hiPSCs that can be used for generation of clinically relevant cell types for cell replacement therapy applications.
Conflict of interest statement
All authors are current or previous employees of Lonza, a pharmaceutical company that develops and sells a wide range of products, including cell-based products for research and pharmaceutical use. Lonza may derive benefit from the sale of a product derived from this research. However, this does not alter our adherence to all the PLOS ONE policies on sharing data and materials.
Figures







Similar articles
-
Synergistic effect of medium, matrix, and exogenous factors on the adhesion and growth of human pluripotent stem cells under defined, xeno-free conditions.Stem Cells Dev. 2012 Jul 20;21(11):2036-48. doi: 10.1089/scd.2011.0489. Epub 2012 Jan 26. Stem Cells Dev. 2012. PMID: 22149941
-
Culture conditions affect cardiac differentiation potential of human pluripotent stem cells.PLoS One. 2012;7(10):e48659. doi: 10.1371/journal.pone.0048659. Epub 2012 Oct 31. PLoS One. 2012. PMID: 23119085 Free PMC article.
-
Controlled Growth and the Maintenance of Human Pluripotent Stem Cells by Cultivation with Defined Medium on Extracellular Matrix-Coated Micropatterned Dishes.PLoS One. 2015 Jun 26;10(6):e0129855. doi: 10.1371/journal.pone.0129855. eCollection 2015. PLoS One. 2015. PMID: 26115194 Free PMC article.
-
Production of human pluripotent stem cell therapeutics under defined xeno-free conditions: progress and challenges.Stem Cell Rev Rep. 2015 Feb;11(1):96-109. doi: 10.1007/s12015-014-9544-x. Stem Cell Rev Rep. 2015. PMID: 25077810 Free PMC article. Review.
-
The safety of human pluripotent stem cells in clinical treatment.Ann Med. 2015;47(5):370-80. doi: 10.3109/07853890.2015.1051579. Epub 2015 Jul 6. Ann Med. 2015. PMID: 26140342 Review.
Cited by
-
Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies.Int J Mol Sci. 2023 Nov 29;24(23):16929. doi: 10.3390/ijms242316929. Int J Mol Sci. 2023. PMID: 38069252 Free PMC article. Review.
-
Characterization of human induced pluripotent stems cells: Current approaches, challenges, and future solutions.Biotechnol Rep (Amst). 2023 Jan 24;37:e00784. doi: 10.1016/j.btre.2023.e00784. eCollection 2023 Mar. Biotechnol Rep (Amst). 2023. PMID: 36818379 Free PMC article. Review.
-
On-demand serum-free media formulations for human hematopoietic cell expansion using a high dimensional search algorithm.Commun Biol. 2019 Feb 1;2:48. doi: 10.1038/s42003-019-0296-7. eCollection 2019. Commun Biol. 2019. PMID: 30729186 Free PMC article.
-
Addressing Manufacturing Challenges for Commercialization of iPSC-Based Therapies.Methods Mol Biol. 2021;2286:179-198. doi: 10.1007/7651_2020_288. Methods Mol Biol. 2021. PMID: 32430594 Review.
-
Human-Induced Pluripotent Stem Cells Manufactured Using a Current Good Manufacturing Practice-Compliant Process Differentiate Into Clinically Relevant Cells From Three Germ Layers.Front Med (Lausanne). 2018 Mar 15;5:69. doi: 10.3389/fmed.2018.00069. eCollection 2018. Front Med (Lausanne). 2018. PMID: 29600249 Free PMC article.
References
-
- Ward CM, Barrow KM, Stern PL (2004) Significant variations in differentiation properties between independent mouse ES cell lines cultured under defined conditions. Exp Cell Res 293: 229–238. - PubMed
-
- Amit M, Shariki C, Margulets V, Itskovitz-Eldor J (2004) Feeder layer- and serum-free culture of human embryonic stem cells. Biol Reprod 70: 837–845. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials